Abstract
Leisure-time physical activity is beneficial for health and is associated with various urban characteristics. Using the exposome framework, the totality of the environment, this study investigated how urban physical environments were associated with leisure-time physical activity during early midlife. A total of 394 participants (mean age: 37, range 34-40) were included from the FinnTwin12 cohort residing in five major Finnish cities in 2020. We comprehensively curated 145 urban physical exposures at residential addresses of participants and measured three leisure-time physical activity measures: (1) total leisure-time physical activity (total LTPA) and its sub-domains (2) leisure-time physical activity without commuting activity (LTPA) and (3) commuting activity. Using K-prototypes cluster analysis, we identified three urban clusters: “original city center,” “new city center,” and “suburban”. Results from adjusted linear regression models showed that participants in the “suburban” cluster had lower levels of total LTPA (beta: -0.13, 95% CI: -0.23, -0.03) and LTPA (beta: -0.17, 95% CI: -0.28, -0.05), compared to those in the “original city center” cluster. The eXtreme Gradient Boosting models ranked exposures related to greenspaces, pocket parks, and road junctions as the top important factors influencing outcomes, and their relationships with outcomes were largely non-linear. More road junctions and more pocket parks correlated with higher total LTPA and LTPA. When the all-year normalized difference vegetation index within a 500 m buffer fell below 0.4, it correlated with higher levels of total LTPA, whereas above 0.4, it correlated with lower levels. To conclude, our findings revealed a positive correlation between urbanicity and physical activity in Finnish cities and decomposed this complexity into crucial determinants. Importance rankings and nonlinear patterns offer valuable insights for future policies and projects targeting physical inactivity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by European Union Horizon 2020 research and innovation program under grant agreement No 874724, National Institute on Alcohol Abuse and Alcoholism (grants AA-12502, AA-00145, and AA-09203 to Richard J. Rose, and AA015416 to Danielle Dick and Jessica Salvatore), Academy of Finland (grants 100499, 205585, 118555, 141054, 264146, 308248, 312073, 336823, 265240, 263278, and 352792 to Jaakko Kaprio), and MCIN/AEI/10.13039/501100011033 (CEX2018-000806-S)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Department of Public Health of the University of Helsinki (Helsinki, Finland) and the Institutional Review Board of Indiana University (Bloomington, Indiana, USA) approved the FinnTwin12 study protocol from the start of the cohort. The ethical approval of the ethics committee of the Helsinki University Central Hospital District (HUS) is the most recent and covers the most recent data collection (early midlife) (HUS/2226/2021, dated September 22, 2021). All participants and their parents/legal guardians gave informed written consent to participate in the study. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The FinnTwin12 data are not publicly available due to the restrictions of informed consent. However, the FinnTwin12 data are available through the Institute for Molecular Medicine Finland (FIMM) Data Access Committee (DAC) (fimm-dac@helsinki.fi) for authorized researchers who have IRB/ethics approval and an institutionally approved study plan. To ensure the protection of privacy and compliance with national data protection legislation, a data use/transfer agreement is needed, the content and specific clauses of which will depend on the nature of the requested data. Requests will be addressed in a reasonable time frame (generally two to three weeks), and the primary mode of data access is by either personal visit or remote access to a secure server.
